Kuros Biosurgery AG   Report issue

For profit Phase 1 Phase 2
Founded: Schlieren Switzerland (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2009
NCT00915486
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kuros BioSciences BV | Kuros Biosurgery | Kuros Biosurgery AG | Kuros Biosurgery AG, Technoparkstrasse 1, CH-8005 Zurich

Active Ingredients

Drugs in Phase 2 Trials (12)

Key: Kuros Biosurgery AG (4) Acquired (8)

autologous bone graft (1 trial)

cyt002-nicqb (1 trial)

cyt003-qbg10 (7 trials)

cyt004-melqbg10 (4 trials)

cyt005-allqbg10 (4 trials)

cyt006-angqb (3 trials)

house dust mite allergen (2 trials)

i-020201 (1 trial)

i-040302 (1 trial)

imiquimod (aldara) (1 trial)

montanide isa 720 (1 trial)

tgplpth1-34 (1 trial)

Drugs in Phase 1 Trials (1)

Key: Kuros Biosurgery AG (0) Acquired (1)

cyt013-il1bqb (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Cysts (Phase 2)

Cysts (Phase 2)

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Intervertebral Disc Degeneration (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 21
  • # of Trial APIs: 13